Tech Company Financing Transactions
Tubulis Funding Round
Andera Partners, Bayern Kapital and BioMedPartners participated in a $63.2 million Series B capital raise for Tubulis. The funding round was recorded on 5/3/2022.
Transaction Overview
Company Name
Announced On
5/3/2022
Transaction Type
Venture Equity
Amount
$63,200,000
Round
Series B
Investors
Andera Partners (Lead Investor) (Sofia Ioannidou)
Proceeds Purpose
The new capital will be used to advance Tubulis' proprietary pipeline of uniquely assembled antibody drug conjugates (ADCs), towards clinical evaluation as well as introduce programs addressing a range of solid tumor indications.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Butenandtstraße 1
Munich, 81377
Germany
Munich, 81377
Germany
Phone
Undisclosed
Website
Email Address
Overview
Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dominik Schumacher
Chief Marketing Officer
Günter Fingerle-Rowson
Chief Scientific Officer
Jonas Helma-Smets
Vice President
Olivier Marcq
VP - Bus. Development
Ingo Lehrke
VP - Regulatory Affairs
Armin Weidmann
Browse more venture capital transactions:
Prev: 5/3/2022: BarRaiser venture capital transaction
Next: 5/3/2022: Stakes venture capital transaction
Share this article
News on VC Transactions
We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs